Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 56.0 Cr.
- Current Price ₹ 47.8
- High / Low ₹ 159 / 19.6
- Stock P/E 17.1
- Book Value ₹ 25.4
- Dividend Yield 0.00 %
- ROCE 14.0 %
- ROE 14.6 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Company has high debtors of 244 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
31.49 | 25.05 | 20.98 | 22.15 | 25.27 | 37.09 | |
30.14 | 23.41 | 19.78 | 20.29 | 20.53 | 31.56 | |
Operating Profit | 1.35 | 1.64 | 1.20 | 1.86 | 4.74 | 5.53 |
OPM % | 4.29% | 6.55% | 5.72% | 8.40% | 18.76% | 14.91% |
0.09 | 0.01 | 0.21 | 0.82 | 0.02 | 0.10 | |
Interest | 0.46 | 0.48 | 0.47 | 0.61 | 0.65 | 0.51 |
Depreciation | 0.77 | 0.68 | 0.68 | 0.71 | 0.72 | 0.74 |
Profit before tax | 0.21 | 0.49 | 0.26 | 1.36 | 3.39 | 4.38 |
Tax % | 47.62% | 40.82% | 61.54% | 28.68% | 28.91% | 25.34% |
0.10 | 0.30 | 0.09 | 0.97 | 2.40 | 3.27 | |
EPS in Rs | 0.17 | 0.50 | 0.15 | 1.62 | 2.79 | 2.79 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | 21% |
TTM: | 47% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 101% |
3 Years: | 231% |
TTM: | 36% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 16% |
Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 6.00 | 6.00 | 6.00 | 6.00 | 8.60 | 11.70 |
Reserves | 1.11 | 1.47 | 1.56 | 2.98 | 6.58 | 18.02 |
8.27 | 9.59 | 10.24 | 11.79 | 12.66 | 12.13 | |
10.44 | 9.28 | 9.27 | 11.82 | 10.75 | 15.59 | |
Total Liabilities | 25.82 | 26.34 | 27.07 | 32.59 | 38.59 | 57.44 |
11.28 | 11.35 | 11.29 | 10.87 | 10.35 | 10.13 | |
CWIP | 0.06 | 0.00 | 0.00 | 0.00 | 0.15 | 2.22 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 |
14.48 | 14.99 | 15.78 | 21.72 | 28.09 | 44.82 | |
Total Assets | 25.82 | 26.34 | 27.07 | 32.59 | 38.59 | 57.44 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
1.58 | -1.16 | 0.04 | -0.58 | -3.69 | -4.91 | |
-0.45 | -0.02 | -0.59 | -0.28 | -0.33 | -2.62 | |
-0.55 | 1.27 | 0.18 | 0.94 | 4.01 | 10.25 | |
Net Cash Flow | 0.58 | 0.09 | -0.37 | 0.07 | -0.01 | 2.72 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 63.98 | 109.72 | 108.73 | 177.47 | 241.21 | 243.56 |
Inventory Days | 101.47 | 61.22 | 128.47 | 225.01 | 244.39 | 127.51 |
Days Payable | 225.45 | 161.56 | 198.97 | 329.82 | 281.81 | 198.67 |
Cash Conversion Cycle | -60.01 | 9.38 | 38.24 | 72.66 | 203.80 | 172.40 |
Working Capital Days | 34.66 | 83.35 | 121.61 | 163.30 | 251.61 | 255.57 |
ROCE % | 5.98% | 4.19% | 10.22% | 16.62% | 14.03% |
Documents
Announcements
-
Press Release
16 June 2025 - Medicamen Organics starts Mauritius operations, launching 22 cosmetics products July 11, targeting 3 Cr sales first year.
-
Analysts/Institutional Investor Meet/Con. Call Updates
10 June 2025 - Medicamen reports 51% revenue growth, invests INR9 Cr in Nepal facility, launches cosmetics, targets 60% CAGR.
-
Analysts/Institutional Investor Meet/Con. Call Updates
4 June 2025 - Audio recording of earnings call for FY25 results available on company website.
-
Press Release
4 June 2025 - Medicamen Organics invests INR 3 Cr to enter beauty segment via subsidiary, targeting global market growth.
-
Investor Presentation
4 June 2025 - Medicamen Organics announces expansions in Rwanda, Mauritius, Nepal with ₹9 Cr investment and new product segments.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPTREC
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.